Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Sloan Ratio % : 0.00% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Fresh Tracks Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

As of Dec. 2023, Fresh Tracks Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Fresh Tracks Therapeutics Sloan Ratio % Historical Data

The historical data trend for Fresh Tracks Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Sloan Ratio % Chart

Fresh Tracks Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

Get a 7-Day Free Trial

-112.47

-15.92

-11.07

-16.75

Fresh Tracks Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sloan Ratio %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Fresh Tracks Therapeutics's Sloan Ratio %

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh Tracks Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Sloan Ratio % falls into.

Fresh Tracks Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Fresh Tracks Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-5.694	-	-4.343
	-	0)	/	11.586
	=	-11.66%

Fresh Tracks Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Dec. 2023 )
	=	(-5.694	-	-4.343
	-	0)	/	11.586
	=	-11.66%

Fresh Tracks Therapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -4.276 (Mar. 2023 ) + -2.284 (Jun. 2023 ) + 2.104 (Sep. 2023 ) + -1.238 (Dec. 2023 ) = $-5.69 Mil.
Fresh Tracks Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -4.485 (Mar. 2023 ) + -1.816 (Jun. 2023 ) + 3.082 (Sep. 2023 ) + -1.124 (Dec. 2023 ) = $-4.34 Mil.
Fresh Tracks Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = $0.00 Mil.

Fresh Tracks Therapeutics (OTCPK:FRTX) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Fresh Tracks Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.

Fresh Tracks Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301